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ABSTRACT 
Objective: Characterize the post-expansion cartilage-forming capacity of chondrocytes 
harvested from detached fragments of osteochondral lesions of ankle joints (Damaged Ankle 
Cartilage Fragments, DACF), with normal ankle cartilage (NAC) as control.  
Design: DACF were obtained from 6 patients (mean age: 35years) with symptomatic 
osteochondral lesions of the talus, while NAC were from 10 autopsies (mean age: 55years). 
Isolated chondrocytes were expanded for two passages and then cultured in pellets for 14 days 
or onto HYAFF®-11 meshes (FAB, Italy) for up to 28 days. Resulting tissues were assessed 
histologically, biochemically (glycosaminoglycan -GAG-, DNA and type II collagen -CII-) 
and biomechanically. 
Results: As compared to NAC, DACF contained significantly lower amounts of DNA (3.0-
fold), GAG (5.3-fold) and CII (1.5-fold) and higher amounts of type-I collagen (6.2-fold). 
Following 14 days of culture in pellets, DACF-chondrocytes generated tissues less intensely 
stained for Safranin-O and CII, with significantly lower GAG contents (2.8-fold). After 28 
days of culture onto HYAFF®-11, tissues generated by DACF chondrocytes were less 
intensely stained for Safranin-O and CII, contained significantly lower amounts of GAG (1.9-
fold) and CII (1.4-fold) and had lower equilibrium (1.7-fold) and dynamic pulsatile modulus 
(3.3-fold) than NAC chondrocytes. 
Conclusion: We demonstrated that DACF-chondrocytes have inferior cartilage forming 
capacity as compared to NAC-chondrocytes, possibly resulting from environmental changes 
associated with trauma/disease. The study opens some reservations on the use of DACF-
derived cells for the repair of ankle cartilage defects, especially in the context of tissue 
engineering-based approaches.  
 
Keywords: chondrogenic differentiation, osteochondral fragments, talar chondrocytes,  
autologous chondrocyte implantation 
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 Running headline: differentiation of damaged cartilage cells 
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INTRODUCTION 
For chondral and osteochondral lesions (OCL) of the talus (ankle joint), different cell-based 
therapies such as the autologous chondrocyte transplantation (ACT) and matrix associated 
ACT are established operative procedures1-3. For these procedures, chondrocytes are 
commonly harvested from the healthy and not affected knee joint3-5. However, a cartilage 
biopsy in a joint, even if harvested from a non-load bearing site, represents an additional 
injury to the cartilage surface, and has been reported to be detrimental to the surrounding 
healthy articular cartilage6.  
Alternatively, cartilage biopsies could be harvested from healthy areas of the osteochondral 
defected ankle joint7. Indeed, promising clinical results were reported when autologous 
chondrocytes derived from cartilage cylinders taken from the anterior part of talus were used 
to restore of full-thickness cartilage defects of such joint4. Moreover, our recent finding that 
chondrocytes isolated from ankle cartilage exhibit similar proliferation ability and post-
expansion tissue-forming capacity than chondrocytes isolated from knee cartilage8 suggest 
that talar chondrocytes may represent a suitable cell source for the repair of cartilage lesions 
of the talus. The harvest of talar chondrocytes from healthy areas of defected ankle joints, 
however, could be detrimental to the function of this already injured joint9. 
To overcome the aforementioned possible problems caused by the harvesting of cartilage 
biopsies from healthy knee or healthy areas of the already affected ankle joint, a rational and 
convenient approach would be represented by the utilization of chondrocytes isolated from 
already detached OCL fragments which are debrided during surgery. In this regard, it was 
reported that viable cells can be isolated from detached osteochondral fragments from human 
articular joints10-11. Moreover, the implantation of such chondrocytes in patients was reported 
to yield good clinical results 12 months post-operatively11. However, the chondrogenic 
capacity of cells isolated from detached OCL fragments remains controversial. While 
Giannini et al (2005)11 reported that these cells have the potential to re-express or synthesise 
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to a certain extent cartilage specific genes and proteins during culture in three-dimensional 
porous scaffolds, Kuroki et al (2002)12, showed that constructs generated by chondrocytes 
from naturally occurring OCL of the humeral head of dogs and cultured in agarose gel formed 
tissues containing inferior amount of glycosaminoglycan, type II collagen and hydroxyproline 
and superior amounts of type I collagen as compared to those generated by chondrocytes from 
healthy cartilage. Similarly, Garvican et al (2008)13 found that chondrogenic differentiation of 
equine chondrocytes from DACF was inferior to that of aged-mached normal chondrocytes. 
The goal of this study was thus to assess the quality of cartilaginous tissues generated by 
human chondrocytes harvested from the detached fragments of OCL of ankle joints 
(Damaged Ankle Cartilage Fragments, DACF), using chondrocytes derived from normal 
ankle cartilage (NAC) as control cells. Cells were cultured in micromass pellets or in 
scaffolds in clinical use for the delivery of human chondrocytes (HYAFF®-11), and the 
resulting tissues assessed phenotypically biochemically and biomechanically. 
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MATERIALS AND METHODS 
Cartilage biopsies 
Damaged ankle cartilage fragments (DACF) were harvested from the talus of 6 patients 
(female:male = 3:3, mean age: 36, age range: 30-43 years) scheduled for surgery of 
symptomatic talar osteochondral lesions of this joint (Table 1), following informed consent. 
Lesions, localized in the middle third of the medial talus edge or at the lateral side, were from 
traumatic origin and not associated with diagnosed instability of the ankle joint. The mean 
time elapsed between the traumatic event and surgery was 6.5 months, which is typically 
sufficient to allow for the onset of early degenerative changes in the joints (e.g., cartilage 
fibrillation in the border of the lesion). The osteochondral lesions, graded according to the 
widely used Berndt & Harty classification (Grade I – V; grade I: subchondral compression; 
grade II: partially avulsed fragment; grade III: detached but not displaced fragment; grade IV: 
displaced fragments; grade V: subchondral cyst)14 were of grade III (5/6) or grade II (1/6) 
(Table 1). During surgery the OCL fragments were found as talar in situ dissecates, carefully 
harvested, and immediately sent from the operation room to the laboratory for further 
analyses.   
As control, normal ankle cartilage (NAC) biopsies were harvested from the healthy areas of 
the talus of 10 cadavers (female:male = 4:6, mean age 55, range 32-79 years) in accordance 
with the Local Ethical Committee8. The chondral layers of DACF and NAC biopsies were 
cleaned meticulously from fibrous tissue and bone, and rinsed several times in a sterile saline 
solution. 
DACF and NAC biopsies were chopped in small pieces which were processed in parallel for 
histology and immunohistochemistry (about 50 mg), for biochemistry (about 50 mg), or for 
chondrocyte isolation (about 100 mg) as described below. 
Chondrocytes isolation and expansion 
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Samples derived from DACF and NAC were digested with 5 ml of type II collagenase (0.15% 
in basic medium – see below – supplemented with 5% foetal bovine serum – FBS –) for 22 
hours8. The isolated chondrocytes were counted using trypan blue, plated in tissue culture 
flasks at a density of 10,000 cells/cm2 and cultured for two passages in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 4.5 mg/ml D-Glucose, 0.1 mM nonessential amino 
acids, 1 mM sodium pyruvate, 100 mM HEPES buffer, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 0.29 mg/ml L-glutamine (basic medium) supplemented with 10% FBS, 1 
ng/ml of Transforming Growth Factor-β1 (TGF-β1) and 5 ng/ml of Fibroblast Growth Factor-
2 in a humidified 37°C/5% CO2 incubator with medium changes twice a week, as previously 
described8. Expanded DACF- and NAC-chondrocytes were harvested for mRNA analysis or 
subsequently cultivated in pellets or in 3D scaffolds, according to previously established 
methods and as briefly described below.  
Chondrocyte cultivation in pellets 
The chondrogenic capacity of expanded DACF- and NAC-chondrocytes was investigated 
using a simple and broadly used model, namely pellet cultures in a defined serum-free 
medium14. Briefly, cells were suspended in basic medium supplemented with ITS+1 (Sigma 
Chemical, St. Louis, MO; i.e., 10 µg/ml insulin, 5.5 mg/ml transferrin, 5 ng/ml selenium, 0.5 
mg/ml bovine serum albumin, 4.7 mg/ml linoleic acid), 0.1 mM ascorbic acid 2-phosphate, 
1.25 mg/ml human serum albumin, 10-7 M dexamethasone and 10 ng/ml TGF-β1 
(chondrogenic medium, CHM). Aliquots of 5x105 cells/0.5 ml were centrifuged at 250 g for 5 
minutes in 1.5 ml polypropylene conical tubes (Sarstedt, Nümbrecht, Germany) to form 
spherical pellets, which were placed onto a 3D orbital shaker (Bioblock Scientific, 
Frenkendorf, Switzerland) at 30 rpm. Pellets were cultured for 2 weeks, with medium changes 
twice per week, and subsequently processed for histological and immunohistochemical or 
biochemical analysis as described below. Each analysis was performed independently in at 
least two entire pellets for each primary culture. 
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Chondrocyte cultivation in 3D scaffolds 
The ability of expanded DACF- and NAC-chondrocytes to generate neo-cartilage was also 
investigated by cultures in esterified hyaluronic acid non-woven meshes (HYAFF®-11, Fidia 
Advanced Biopolymers, Abano Terme, IT), currently in clinical use for cartilage repair15 
since such model allows more extensive cartilaginous tissue maturation than in pellets over 
prolonged culture times16. Chondrocytes were loaded statically on the scaffolds (6 mm 
diameter, 2 mm thick disks) at a density of 4x106 cells/scaffold. Cell-scaffold constructs were 
cultured in basic medium supplemented with 0.1 mM ascorbic acid, 10 µg/ml Insulin and 10 
ng/ml Transforming Growth Factor-β3, with medium changes twice a week, as previously 
described8. After 14 or 28 days of static culture, the resulting tissues were analysed 
histologically, immunohistochemically, biochemically and biomechanically, as described 
below.  
Analytical Methods 
Proliferation rate 
Cell proliferation rate was calculated as the ratio of T to log2(N/N0), where N0 and N are the 
numbers of cells respectively at the beginning and the end of the expansion phase, and T is 
the time required for the expansion17.  
Histological and immunohistochemical analyses 
DACF and NAC tissues and engineered tissues (pellets and constructs) were rinsed with PBS, 
fixed in 4% formalin, embedded in paraffin, and cross-sectioned (5 µm thick for pellets and 7 
µm thick for constructs and native tissues). Sections were stained with Safranin-O for sulfated 
glycosaminoglycans (GAG), with or without additional staining with 5% Silver nitrate 
solution (von Kossa staining for mineralized matrix detection), or processed for immuno-
histochemistry using antibodies against type I collagen (Quartett, Berlin, Germany) and type 
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II collagens (II-II6B3, Hybridoma Bank, University of Iowa, USA) as previously described18-
19. 
Biochemical Analysis 
DACF, NAC and engineered constructs were cut in different pieces, part of them were 
lyophilized the remaining parts were blotted dry. Specimens were first weighed and 
subsequently digested for 15 hours at 56°C with protease K (1.0 ml of 1 mg/ml protease K in 
50 mM Tris with 1 mM EDTA, 1 mM iodoacetamide and 10 µg/ml pepstatin-A). Pellets were 
digested with the same protocol but using 0.5 ml protease K. GAG amounts were measured 
spectrophotometrically after reaction with dimethylmethylene blue20, with chondroitin sulfate 
as a standard21. The DNA amount was measured spectrofluorometrically using the 
CyQUANT® Kit (Molecular Probes, Eugene, USA) following the kit’s instruction with calf 
thymus DNA as a standard. GAG contents were reported as % GAG/ dry weight tissue for 
DACF and NAC and engineered constructs or as GAG/DNA for pellets. DNA contents were 
reported as % DNA/ dry weight tissue for DACF and NAC. 
For the determination of type I and II collagens, DACF NAC and cartilaginous constructs 
were first lyophilized. The dried samples were fully solubilised by digestion with 2 mg/ml 
Tosylamide-2-phenylethyl chloromethyl ketone-treated bovine pancreatic trypsin in 50 mM 
Tris-HCl, pH 7.6, containing 1mM iodoacetamide, 1mM EDTA and 10 µg/ml pepstatin A, 
using an initial incubation of 15 h at 37ºC followed by a further 2 h incubation at 65ºC after 
the addition of fresh trypsin. Samples were boiled for 15 min to inactivate the enzyme22. 
Amounts of type II collagen were assayed by inhibition ELISA using a mouse IgG 
monoclonal antibody to denatured type II collagen23. Amounts of type I collagen were 
assayed by inhibition ELISA using a rabbit anti-peptide antibody to type I collagen22. 
Real-time quantitative RT-PCR assays 
RNA of expanded DACF- and NAC-chondrocytes was extracted using Trizol (Life 
Technologies, Basel, Switzerland), according to the Manufacturer’s protocol. RNA was 
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treated with DNAseI using the DNA-freeTM Kit (Ambion, USA) and quantified 
spectrophotometrically. cDNA was generated from 3 μg of RNA by using 500 μg/ml random 
hexamers (Catalys AG, CH) and 1 μl of 50 U/ml StratascriptTM reverse transcriptase 
(Stratagene, NL), in the presence of dNTPs. PCR reactions were performed and monitored 
using the ABI Prism 7700 Sequence Detection System (Perkin-Elmer/Applied Biosystems, 
Rotkreuz, Switzerland). Cycle temperatures and times as well as primers and probes used for 
the reference gene (18-S rRNA) and the genes of interest (type I collagen and type II 
collagen), were as previously described24. For each cDNA sample, the threshold cycle (Ct) 
value of 18-S was subtracted from the Ct value of the target gene, to derive ∆Ct. The levels of 
expression of type I and type II collagen were calculated as 2∆Ct and represented in 
logarithmic scale. Each sample was assessed at least in duplicate for each gene of interest. 
Biomechanical analysis 
Mechanical tests on constructs were conducted in a standard miniature test instrument in 
unconfined compression (Synergie 100, MTS Systems Corp., Eden Prairie MN, USA) to 
measure the Equilibrium modulus (EEQ) and the Pulsatile dynamic modulus (EPD), as 
previously described in detail25. Briefly, EEQ was determined from a linear regression of the 
data pairs of equilibrium stress/incremental strain, following application of five incremental 
strains of 5% and computation of the corresponding equilibrium stress. EPD was calculated as 
the slope of the stress/strain curve, after exposing specimens to five cycles of  compressive 
loading/unloading at 0.17 mm/s, reaching a strain of 20% and with each strain period 
followed by a no-load period of time equal to that for loading/unloading.  
Statistical analysis 
Unless otherwise stated, values are presented as mean ± standard error of measurements 
(SEM) using cells from 6 donors for the experimental group (i.e.: DACF) and cells from 10 
donors for the control group (i.e.: NAC). Statistical analyses were performed using the Sigma 
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Stat software (SPSS Inc., Version13). Differences between groups were assessed by Mann-
Whitney test and considered statistically significant when p values were lower than 0.05.  
 
RESULTS 
Cellular and extracellular matrix (ECM) contents in Damaged Ankle Cartilage 
Fragments (DACF) and Normal Ankle Cartilage (NAC) biopsies 
Macroscopically, DACF appeared rough and dull. As compared to NAC biopsies, DACF 
were less cellular, as evidenced by a statistically significant lower amount of DNA (3.0-fold). 
Quantitative assessments of the ECM indicated that DACF contained statistically significant 
lower amounts of GAG (5.3-fold) and type II collagen (1.5-fold) but higher amounts of type I 
collagen (6.2-fold) (Table 2). Histological and immunohistochemical assessments indicated 
that: (i) staining for GAG and type II collagen were faint and/or scattered in restricted areas of 
the DACF but strongly and uniformly distributed in NAC, (ii) staining for type I collagen was 
diffuse in DACF whereas localized in the thin superficial layer of NAC, (iii) staining for Von 
Kossa was diffuse in DACF whereas restricted at the cartilage-bone interface in NAC, (iv) 
cells with fibroblastic morphology were present within the DACF but absent or  localized in 
the thin superficial layer of NAC, (v) clusters of cells were present abundantly only within the 
DACF (Fig. 1).  
Cell yield, proliferation rate and differentiation stage of DACF- and NAC-chondrocytes 
In agreement with the DNA quantification results, DACF yielded statistically significant 
lower number of cells as compared to NAC (respectively 1.7 ± 0.6 × 105 and 3.5 ± 0.6 × 105 
cells/100mg of tissues processed for cell expansion) following enzymatic digestion of 
specimens.  
DACF- and NAC-chondrocytes cultured in monolayers exhibited similar elongated and 
spindle-shaped morphologies characteristic of de-differentiated chondrocytes (Fig 2A). As 
compared to NAC-chondrocytes, DACF-chondrocytes (i) proliferated at higher rate (p>0.05) 
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(cells underwent respectively 7.8 ± 1.2 and 10.4 ± 1.0 doublings in 15 ± 2 days; Fig. 2B) and 
(ii) expressed higher type I collagen (4.2-fold; p>0.05) and lower type II collagen (3.1-fold; 
p>0.05) mRNA levels, with consequently lower (21.6-fold) type II/type I collagen mRNA 
ratio (Fig. 2C). The above described trends were not, however, statistically significant. The 
extent of cell expansion within the 2 passages was sufficient to generate at least about 50 × 
106 cells from 100 mg biopsy, which was sufficient for the subsequent differentiation assays 
and would be clinically relevant for implantation or for engineering of a cartilage graft. 
Post-expansion chondrogenic capacity in cell pellets 
Expanded DACF-chondrocytes exhibited a generally poor re-differentiation capacity in pellet 
culture. Tissues generated with this model in fact (i) resulted negatively stained for GAG (5/6) 
or positively stained only in scattered regions (1/6, donor 3) and (ii) contained cells with 
necrotic or fibroblastic appearances. Instead, pellets generated by NAC-chondrocytes were 
uniformly stained for GAG and contained cells with the typical chondrocytic round 
morphology (Fig. 3A). Biochemical assessment confirmed a statistically significant lower 
content of GAG (2.8-fold) in pellets generated by DACF-chondrocytes. DACF-chondrocytes 
from only one donor (donor 3) accumulated GAG at levels approaching the average ones 
measured for NAC-chondrocytes8 (Fig 3B). DNA contents of pellets generated by the two cell 
types were similar (less than 10% of variation between the two groups). 
Immunohistochemical analysis showed that type II collagen was absent (5/6) or accumulated 
only in limited region of pellets (1/6, donor 3) generated by DACF-chondrocytes. In contrast, 
pellets generated by NAC-chondrocytes were uniformly stained for type II collagen (Fig. 3C). 
Tissue-forming capacity in 3D scaffolds 
After 14 days of culture in HYAFF-11® meshes, tissues based on DACF-chondrocytes were 
negatively stained for GAG and type II collagen while the tissues based on NAC-
chondrocytes were faintly stained for both proteins. At the same time, tissues generated by 
both DACF- and NAC-chondrocytes had similar amounts of DNA and contained cells with 
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fibroblastic appearance (data not shown). After 28 days of culture, tissues generated by 
DACF-chondrocytes remained negatively stained for GAG (5/6) or accumulated ECM faintly 
stained for GAG (1/6, donor 3) in restricted regions, and contained predominantly fibroblastic 
cells. At this time point, tissues generated by DACF chondrocytes had significantly lower 
DNA content than those generated by NAC-chondrocytes (1.5-fold), likely indicating the 
reduced capacity of the former chondrocytes to proliferate within the scaffolds. Staining for 
type II collagen was negative in all constructs. Instead, tissues generated by NAC 
accumulated large amounts of ECM positively stained for GAG and type II collagen and 
contained a large fraction of cells with a chondrocytic morphology (Fig. 4A). 
Biochemical analysis generally confirmed the histological observations. GAG and type II 
collagen as a % of dry weight did not increase from 14 to 28 days of culture in constructs 
based on DACF-chondrocytes, and thus remained at statistically significant lower levels than 
those measured in constructs based on NAC-chondrocytes (1.9- and 1.7-fold respectively). 
Instead, type I collagen markedly increased with culture time (3.3-fold), resulting, at 28 days, 
in higher amounts (1.5-fold) in constructs based on DACF-chondrocytes than in those based 
on NAC-chondrocytes (Fig. 4B). At the latest culture time the ratio of type II to type I 
collagen was 2.9-fold higher in constructs based on NAC-chondrocytes. 
The measured biomechanical properties of tissues captured the biochemical differences (Fig. 
4C). In fact, equilibrium modulus and dynamic pulsatile modulus (i) did not significantly 
increase between 14 and 28 days of culture in constructs based on DACF-chondrocytes, and 
(ii) were significantly lower in constructs based on DACF-chondrocytes as compared to those 
based of NAC-chondrocytes (1.7- and 3.3-fold respectively) after 28 days of culture.  
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DISCUSSION  
In this study, chondrocytes harvested from the detached fragments of osteochondral lesions 
(OCL) of ankle joints (Damaged Ankle Cartilage Fragments, DACF) and from normal 
articular cartilage (NAC) of the talus of cadavers were compared in terms of their growth and 
de-differentiation during two-dimensional culture, as well as of their post-expansion tissue 
forming capacity. DACF chondrocytes displayed more fibroblastic characteristics, as 
evidenced by the trends of higher proliferation rate and higher extent of de-differentiation. 
When induced to re-differentiate in pellet culture or in porous scaffolds, DACF-chondrocytes 
produced tissues with lower GAG and type II collagen contents and lower biomechanical 
properties. 
Histological and biochemical assessments of the harvested DACF indicate that such tissues 
contained markedly lower amount of proteoglycans and type II collagen and higher amounts 
of type I collagen as compared to NAC. Interestingly, a large portion of the dry weight of 
DACF remains unaccounted for by the measured extracellular components and likely 
consisted of macromolecules produced to a larger extent by more fibroblastic cells (e.g., type 
III collagen and versican) or of mineral deposits, since in fact large areas of fibrocartilage and 
mineralized cartilage were observed in the DACF. Although our harvested DACF were from 
slightly older patients as compared to those of Giannini et al (2005)11 (mean age: 36.3 years 
and 30.5 years, respectively), our data do not support the previously reported results11. 
Moreover our study is the first to more thoroughly compare the re-differentiation capacity of 
DACF-chondrocytes to that of NAC-chondrocytes, including a biochemical and 
biomechanical characterization of the in vitro generated tissues. The findings are generally in 
line with those reported by Aurich et al (2005)10 and Garvican et al (2008)13, describing that 
OCL chondrocytes display rather fibroblastic features. 
Our results clearly show that DACF-chondrocytes exhibit a reduced re-differentiation 
capacity in pellets as compared to NAC-chondrocytes, as assessed by a reduced accumulation 
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of GAG and type II collagen. Due to the relatively limited amount of DACF analysed, we 
could not observe clear correlations between chondrogenesis and either patient age or the 
interval between trauma and the operation. Although the models here used to investigate the 
cartilage forming ability have been previously validated using a variety of different 
chondrogenic cell types16,26, we cannot exclude that the presence of growth factors during the 
phases of cell expansion/differentiation could have critically determined the observed 
differences. 
Similary to our results, Garvican et al (2008)13 have recently found that pellets generated by 
chondrocytes from equine OCL contained significantly lower GAG and expressed 
significantly less amount of Sox9 than pellets created from normal chondrocytes. Interestingly 
in the same study the authors observed that OCL chondrocytes expressed higher levels of 
MMP-13 mRNA as compared to normal chondrocytes. Therefore, the impaired capacity of 
OCL (vs normal) chondrocytes to re-differentiate could be a consequence of both decreased 
synthesis and increased degradation of ECM. The observations reported for OCL 
chondrocytes should not be generalized to other cartilage pathologies, since it was recently 
demonstrated that chondrocytes from osteoarthritic patients display a normal chondrogenic 
differentiation capacity27.  
We are aware that the models used in the present study to characterize the post-expansion 
chondrogenic capacity of DACF chondrocytes (i.e., static culture in the presence of 
chondrogenic factors), have not been validated to directly predict the reparative ability of the 
cell types when implanted in the talar lesions. In a recent work, Giannini et al (2008)28 
reported results of a clinical study in which 46 patients with focal talar dome osteochondral 
lesion were treated with ACI using HYAFF-11® and chondrocytes harvested from the 
detached OCL fragments or from tissue harvested from the margin of the lesion or from the 
anterior margin of the tibia. The authors however did not describe differences in the clinical 
outcome of patients treated with the different cell sources. Controlled randomized clinical 
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trials are therefore necessary to compare clinical outcome of cell based cartilage repair 
technique based on the DACF- and NAC-chondrocytes. 
 
In conclusion, our results indicate that chondrocytes isolated from DACF have inferior 
cartilage forming capacity as compared to chondrocytes from normal ankle cartilage tissues, 
probably resulting from environmental changes occurring during and after OCL 
trauma/disease. The study opens some reservations on the use of DACF-derived cells for the 
repair of ankle cartilage defects, especially in the context of tissue engineering-based 
approaches, since DACF-chondrocytes would not be able to generate functional cartilaginous 
tissues in vitro. Further investigations are required to assess whether the use of culture 
conditions including different biochemical and biomechanical cues, or sorting of 
subpopulations expressing higher levels of markers associated with the cell chondrogenic 
capacity29, could enhance the cartilage forming ability of DACF-chondrocytes. 
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LEGEND TO FIGURES 
Figure 1. Histological appearance of detached fragments of osteochondral lesions of 
ankle joints (Damaged Ankle Cartilage Fragments, DACF) and normal articular 
cartilage (NAC). 
Safranin O (A, B), Von Kossa/Safranin O staining (B), type II collagen and type I collagen 
immunohistochemical staining (A) of DACF harvested from two different, representative 
donors: donor 3 (I) and donor 5 (II) (see Table 1 for the donor information) and of normal 
articular cartilage (NAC) harvested from a cadaveric joint of a young individual (male, 32 
years) (III). Bar = 100 µm. Arrows indicate cartilage/bone interface, asterisks show cell 
clusters, h = hyaline or hyaline-like cartilage, f = fibrocartilage, c = calcified cartilage.   
Figure 2.  Growth and differentiation stage of chondrocytes isolated from Damaged 
Ankle Cartilage Fragments (DACF) and normal articular cartilage (NAC) 
(A) Representative phase-contrast pictures of expanded DACF-chondrocytes (I) and NAC-
chondrocytes (II) (see Table 1 for the donor information). Bar = 100 µm. (B) Proliferation 
rate of DACF- and NAC-chondrocytes. Values are the mean ± SEM of measurements 
obtained from 6 different DACF or 10 different NAC. (C) Real time reverse transcriptase-
polymerase chain reaction analysis of the expression of mRNA for type I (CI) and type II 
(CII) collagens (left y axis labelling) or the CII/CI ratio (right y labelling axis). Values are the 
mean ± SEM of measurements obtained from 4 different DACF or 4 different NAC. 
Figure 3. Differentiation capacity of chondrocytes isolated from Damaged Ankle 
Cartilage Fragments (DACF) and normal articular cartilage (NAC) in pellets 
(A) Safranin O stainings of representative pellets generated by DACF-chondrocytes harvested 
from two different donors: donor 3 (I), donor 5 (II) (see Table 1 for the donor information) 
and NAC-chondrocytes harvested from a cadaveric joint of a young individual (male, 32 
years) (III) Bar = 100 µm. (B) Sulfate glycosaminoglycan (GAG) content normalized to the 
amount of DNA in pellets. Values are the mean ± SEM of triplicate pellets. The plotted lines 
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indicate mean values measured in pellets generated by cells from NAC (upper line, 10 donors, 
mean ± SEM = 13.1 ± 1.6) or DACF (bottom line, 6 donors, mean ± SEM = 4.6 ± 1.6). (C) 
Type II collagen immunohistochemical stainings of representative pellets generated by 
DACF-chondrocytes harvested from two different donors: donor 2 (I), donor 3 (II) and NAC-
chondrocytes harvested from a cadaveric joint of a young individual (male, 32 years) (III).  
Figure 4. Differentiation capacity of chondrocytes isolated from Damaged Ankle 
Cartilage Fragments (DACF) and normal articular cartilage (NAC) in HYAFF-11® 
scaffold. 
Safranin O stainings (A) and type II collagen immunohistochemical stainings (B) of 
representative constructs generated by DACF-chondrocytes harvested from two different 
donors [donor 3 (I), donor 5 (II) (see Table 1 for the donor information)] and NAC-
chondrocytes harvested from a cadaveric joint of a young individual (male, 32 years) (III) 
cultured in chondrogenic medium for 28 days. Bar = 100 µm. h = hyaline-like cartilage, f = 
fibrocartilage (C) Amounts of sulphate glycosaminoglycan (GAG), type I collagen and type II 
collagen accumulated in constructs generated by DACF-chondrocytes (bars, 6 donors) and 
NAC-chondrocytes (plotted line, 10 donors, values as mean ± SEM equal to: 9.9 ± 1.5, 4.2 ± 
0.6 and 1.3 ± 0.4 respectively for GAG, type I collagen and type II collagen) expressed as a 
percentage of tissue dry weight. (D) Equilibrium modulus and dynamic pulsatile modulus of 
constructs generated by DACF-chondrocytes (bars, 6 donors) and NAC-chondrocytes (plotted 
line, 10 donors, values as mean ± SEM equal to: 29.9 ± 4.4 and 1.6 ± 0.1 respectively for 
equilibrium modulus and dynamic pulsatile modulus). * = significantly different from the 
NAC group at the corresponding time point, ° = significantly different from 2 weeks.  
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Table 1 Patient information for osteochondral lesions (OCL)  
 Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Gender female male male female male female 
Age  30 years 43 years 39 years 36 years 33 years 37 years 
Joint side medial medial lateral medial lateral medial 
OCL Grade  
(Berndt & Harty) 
III III III II III III 
Interval 
trauma/operation 
14 months 3 months 6 months 6 months 4 months 6 months 
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